标题
Markers of Response for the Antiangiogenic Agent Bevacizumab
作者
关键词
-
出版物
JOURNAL OF CLINICAL ONCOLOGY
Volume 31, Issue 9, Pages 1219-1230
出版商
American Society of Clinical Oncology (ASCO)
发表日期
2013-02-12
DOI
10.1200/jco.2012.46.2762
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Polymorphisms in VEGF, eNOS, COX-2, and IL-8 as predictive markers of response to bevacizumab.
- (2017) L. lo Giudice et al. JOURNAL OF CLINICAL ONCOLOGY
- Pharmacokinetics (PK) of pegylated liposomal doxorubicin (PLD) given alone and with bevacizumab (B) in patients with recurrent epithelial ovarian cancer (rEOC).
- (2017) F. Muggia et al. JOURNAL OF CLINICAL ONCOLOGY
- Predictive and prognostic potential of angiogenic serum factors and circulating endothelial cells in metastatic melanoma patients receiving temozolamide plus bevacizumab (SAKK 50/07).
- (2017) G. Fuerstenberger et al. JOURNAL OF CLINICAL ONCOLOGY
- Vascular endothelial growth factors (VEGF) and VEGF receptor expression as predictive biomarkers for benefit with bevacizumab in metastatic colorectal cancer (mCRC): Analysis of the phase III MAX study.
- (2017) A. J. Weickhardt et al. JOURNAL OF CLINICAL ONCOLOGY
- Inhibiting Angiogenesis in Breast Cancer: The Beginning of the End or the End of the Beginning?
- (2012) Hope S. Rugo JOURNAL OF CLINICAL ONCOLOGY
- Addition of Aflibercept to Fluorouracil, Leucovorin, and Irinotecan Improves Survival in a Phase III Randomized Trial in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin-Based Regimen
- (2012) Eric Van Cutsem et al. JOURNAL OF CLINICAL ONCOLOGY
- Bevacizumab in Combination With Chemotherapy As First-Line Therapy in Advanced Gastric Cancer: A Biomarker Evaluation From the AVAGAST Randomized Phase III Trial
- (2012) Eric Van Cutsem et al. JOURNAL OF CLINICAL ONCOLOGY
- Resistance and Escape From Antiangiogenesis Therapy: Clinical Implications and Future Strategies
- (2012) Justin N. Bottsford-Miller et al. JOURNAL OF CLINICAL ONCOLOGY
- VEGF pathway genetic variants as biomarkers of treatment outcome with bevacizumab: an analysis of data from the AViTA and AVOREN randomised trials
- (2012) Diether Lambrechts et al. LANCET ONCOLOGY
- Dynamic contrast-enhanced MRI in clinical trials of antivascular therapies
- (2012) James P. B. O'Connor et al. Nature Reviews Clinical Oncology
- Efficacy, Safety, and Biomarkers of Single-Agent Bevacizumab Therapy in Patients with Advanced Hepatocellular Carcinoma
- (2012) V. Boige et al. ONCOLOGIST
- Efficacy of Bevacizumab plus Erlotinib for Advanced Hepatocellular Carcinoma and Predictors of Outcome: Final Results of a Phase II Trial
- (2012) A.O. Kaseb et al. ONCOLOGY
- Phase I Study of Cetuximab, Irinotecan, and Vandetanib (ZD6474) as Therapy for Patients with Previously Treated Metastastic Colorectal Cancer
- (2012) Jeffrey A. Meyerhardt et al. PLoS One
- Retrospective exploratory analysis of VEGF polymorphisms in the prediction of benefit from first-line FOLFIRI plus bevacizumab in metastatic colorectal cancer
- (2011) Fotios Loupakis et al. BMC CANCER
- Pharmacodynamic and pharmacogenetic angiogenesis-related markers of first-line FOLFOXIRI plus bevacizumab schedule in metastatic colorectal cancer
- (2011) F Loupakis et al. BRITISH JOURNAL OF CANCER
- Abstract P2-16-04: Plasma Biomarker Analyses in the AVADO Phase III Randomized Study of First-Line Bevacizumab + Docetaxel in Patients with Human Epidermal Growth Factor Receptor (HER) 2-Negative Metastatic Breast Cancer:
- (2011) DW Miles et al. CANCER RESEARCH
- Basic and Therapeutic Aspects of Angiogenesis
- (2011) Michael Potente et al. CELL
- Impact of Exploratory Biomarkers on the Treatment Effect of Bevacizumab in Metastatic Breast Cancer
- (2011) A. M. Jubb et al. CLINICAL CANCER RESEARCH
- Pharmacogenetic Angiogenesis Profiling for First-line Bevacizumab plus Oxaliplatin-Based Chemotherapy in Patients with Metastatic Colorectal Cancer
- (2011) A. Gerger et al. CLINICAL CANCER RESEARCH
- 1414 POSTER Single Nucleotide Polymorphism Analysis and Outcome in Advanced-stage Cancer Patients Treated With Bevacizumab
- (2011) D. Lambrechts et al. EUROPEAN JOURNAL OF CANCER
- 1423 POSTER Polymorphism Analysis in the AVADO Randomised Phase III Trial of First-line Bevacizumab (BEV) Combined With Docetaxel in HER2-negative Metastatic Breast Cancer (mBC)
- (2011) D.W. Miles et al. EUROPEAN JOURNAL OF CANCER
- 803 ORAL Analysis of Blood Plasma Factors in the AVITA Phase III Randomized Study of Bevacizumab (bev) With Gemcitabine-Erlotinib (GE) in Patients (pts) With Metastatic Pancreatic Cancer (mPC)
- (2011) E. Van Cutsem et al. EUROPEAN JOURNAL OF CANCER
- 9003 ORAL Biomarker Analysis in BO21015, a Phase II Randomised Study of First-line Bevacizumab (BEV) Combined With Carboplatin-gemcitabine (CG) or Carboplatin-paclitaxel (CP) in Patients (pts) With Advanced or Recurrent Non-squamous Non-small Cell Lung Cancer (NSCLC)
- (2011) T. Mok et al. EUROPEAN JOURNAL OF CANCER
- The predictive value of single nucleotide polymorphisms in the VEGF system to the efficacy of first-line treatment with bevacizumab plus chemotherapy in patients with metastatic colorectal cancer
- (2011) Torben Frøstrup Hansen et al. INTERNATIONAL JOURNAL OF COLORECTAL DISEASE
- Upregulated stromal EGFR and vascular remodeling in mouse xenograft models of angiogenesis inhibitor–resistant human lung adenocarcinoma
- (2011) Tina Cascone et al. JOURNAL OF CLINICAL INVESTIGATION
- Pazopanib Efficacy in Renal Cell Carcinoma: Evidence for Predictive Genetic Markers in Angiogenesis-Related and Exposure-Related Genes
- (2011) Chun-Fang Xu et al. JOURNAL OF CLINICAL ONCOLOGY
- Impact ofKRASandBRAFGene Mutation Status on Outcomes From the Phase III AGITG MAX Trial of Capecitabine Alone or in Combination With Bevacizumab and Mitomycin in Advanced Colorectal Cancer
- (2011) Timothy J. Price et al. JOURNAL OF CLINICAL ONCOLOGY
- RIBBON-1: Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Chemotherapy With or Without Bevacizumab for First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative, Locally Recurrent or Metastatic Breast Cancer
- (2011) Nicholas J. Robert et al. JOURNAL OF CLINICAL ONCOLOGY
- A vascular niche and a VEGF–Nrp1 loop regulate the initiation and stemness of skin tumours
- (2011) Benjamin Beck et al. NATURE
- Molecular mechanisms and clinical applications of angiogenesis
- (2011) Peter Carmeliet et al. NATURE
- Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases
- (2011) Peter Carmeliet et al. NATURE REVIEWS DRUG DISCOVERY
- Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer
- (2011) Robert A. Burger et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Phase 3 Trial of Bevacizumab in Ovarian Cancer
- (2011) Timothy J. Perren et al. NEW ENGLAND JOURNAL OF MEDICINE
- Vascular endothelial growth factor polymorphisms and clinical outcome in colorectal cancer patients treated with irinotecan-based chemotherapy and bevacizumab
- (2011) A K Koutras et al. PHARMACOGENOMICS JOURNAL
- Normalization of the Vasculature for Treatment of Cancer and Other Diseases
- (2011) Shom Goel et al. PHYSIOLOGICAL REVIEWS
- Phase II trial of neoadjuvant temozolomide in resectable melanoma patients
- (2010) G. D. Shah et al. ANNALS OF ONCOLOGY
- Identification of serum angiopoietin-2 as a biomarker for clinical outcome of colorectal cancer patients treated with bevacizumab-containing therapy
- (2010) V Goede et al. BRITISH JOURNAL OF CANCER
- Plasma Cytokine and Angiogenic Factor Profiling Identifies Markers Associated with Tumor Shrinkage in Early-Stage Non-Small Cell Lung Cancer Patients Treated with Pazopanib
- (2010) P. G. Nikolinakos et al. CANCER RESEARCH
- The predictive value of serum VEGF in multiresistant ovarian cancer patients treated with bevacizumab
- (2010) M.P. Smerdel et al. GYNECOLOGIC ONCOLOGY
- Phase III Study of Bevacizumab Plus Docetaxel Compared With Placebo Plus Docetaxel for the First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer
- (2010) David W. Miles et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Study of Cediranib, an Oral Pan–Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Recurrent Glioblastoma
- (2010) Tracy T. Batchelor et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase III Trial of Bevacizumab Plus Interferon Alfa-2a in Patients With Metastatic Renal Cell Carcinoma (AVOREN): Final Analysis of Overall Survival
- (2010) Bernard Escudier et al. JOURNAL OF CLINICAL ONCOLOGY
- Lessons From the Adjuvant Bevacizumab Trial on Colon Cancer: What Next?
- (2010) Eric Van Cutsem et al. JOURNAL OF CLINICAL ONCOLOGY
- Refocusing the War on Cancer: The Critical Role of Personalized Treatment
- (2010) A. Potti et al. Science Translational Medicine
- PDGF-C Mediates the Angiogenic and Tumorigenic Properties of Fibroblasts Associated with Tumors Refractory to Anti-VEGF Treatment
- (2009) Yongping Crawford et al. CANCER CELL
- Direct Evidence that Bevacizumab, an Anti-VEGF Antibody, Up-regulates SDF1 , CXCR4, CXCL6, and Neuropilin 1 in Tumors from Patients with Rectal Cancer
- (2009) L. Xu et al. CANCER RESEARCH
- Heterozygous Deficiency of PHD2 Restores Tumor Oxygenation and Inhibits Metastasis via Endothelial Normalization
- (2009) Massimiliano Mazzone et al. CELL
- A Vasculature-Targeting Regimen of Preoperative Docetaxel with or without Bevacizumab for Locally Advanced Breast Cancer: Impact on Angiogenic Biomarkers
- (2009) J. Baar et al. CLINICAL CANCER RESEARCH
- Neuropilins in Tumor Biology
- (2009) A. Bagri et al. CLINICAL CANCER RESEARCH
- 9172 Analysis of biomarkers (BMs) in the AVAiL phase III randomised study of first-line Bevacizumab (Bv) with cisplatin-gemcitabine (CG) in patients (pts) with non-small cell lung cancer (NSCLC)
- (2009) N. Leighl et al. EJC SUPPLEMENTS
- Association of Computed Tomography Morphologic Criteria With Pathologic Response and Survival in Patients Treated With Bevacizumab for Colorectal Liver Metastases
- (2009) Yun Shin Chun JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Phase II Study of Cisplatin Plus Etoposide and Bevacizumab for Previously Untreated, Extensive-Stage Small-Cell Lung Cancer: Eastern Cooperative Oncology Group Study E3501
- (2009) Leora Horn et al. JOURNAL OF CLINICAL ONCOLOGY
- Predictors of Primary Imatinib Resistance in Chronic Myelogenous Leukemia Are Distinct From Those in Secondary Imatinib Resistance
- (2009) Wenyong W. Zhang et al. JOURNAL OF CLINICAL ONCOLOGY
- Efficacy, Safety, and Potential Biomarkers of Sunitinib Monotherapy in Advanced Hepatocellular Carcinoma: A Phase II Study
- (2009) Andrew X. Zhu et al. JOURNAL OF CLINICAL ONCOLOGY
- Efficacy, Safety, and Biomarkers of Neoadjuvant Bevacizumab, Radiation Therapy, and Fluorouracil in Rectal Cancer: A Multidisciplinary Phase II Study
- (2009) Christopher G. Willett et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Trial of Infusional Fluorouracil, Irinotecan, and Bevacizumab for Metastatic Colorectal Cancer: Efficacy and Circulating Angiogenic Biomarkers Associated With Therapeutic Resistance
- (2009) Scott Kopetz et al. JOURNAL OF CLINICAL ONCOLOGY
- Role and Therapeutic Potential of VEGF in the Nervous System
- (2009) Carmen Ruiz de Almodovar et al. PHYSIOLOGICAL REVIEWS
- Polymorphisms and Clinical Outcome in Recurrent Ovarian Cancer Treated with Cyclophosphamide and Bevacizumab
- (2008) A. M. Schultheis et al. CLINICAL CANCER RESEARCH
- Cell Adhesion Molecules, Vascular Endothelial Growth Factor, and Basic Fibroblast Growth Factor in Patients with Non-Small Cell Lung Cancer Treated with Chemotherapy with or without Bevacizumab--an Eastern Cooperative Oncology Group Study
- (2008) A. Dowlati et al. CLINICAL CANCER RESEARCH
- Genetics, epigenetics and pharmaco-(epi)genomics in angiogenesis
- (2008) Ian Buysschaert et al. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
- Response-Independent Survival Benefit in Metastatic Colorectal Cancer: A Comparative Analysis of N9741 and AVF2107
- (2008) Axel Grothey et al. JOURNAL OF CLINICAL ONCOLOGY
- Association of Vascular Endothelial Growth Factor and Vascular Endothelial Growth Factor Receptor-2 Genetic Polymorphisms With Outcome in a Trial of Paclitaxel Compared With Paclitaxel Plus Bevacizumab in Advanced Breast Cancer: ECOG 2100
- (2008) Bryan P. Schneider et al. JOURNAL OF CLINICAL ONCOLOGY
- Bevacizumab in Combination With Oxaliplatin-Based Chemotherapy As First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III Study
- (2008) Leonard B. Saltz et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Trial of Single-Agent Bevacizumab Followed by Bevacizumab Plus Irinotecan at Tumor Progression in Recurrent Glioblastoma
- (2008) Teri N. Kreisl et al. JOURNAL OF CLINICAL ONCOLOGY
- High-grade glioma before and after treatment with radiation and Avastin: Initial observations
- (2008) Ingeborg Fischer et al. NEURO-ONCOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started